Understanding the ‘Cicada’ COVID-19 Variant: What You Require to Know About BA.3.2

Health officials are closely monitoring a modern SARS-CoV-2 lineage known as BA.3.2, which has earned the nickname “Cicada.” While this variant has been circulating quietly for some time, recent data from the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) indicate an increase in detections globally and within the United States.

The primary concern for public health experts isn’t necessarily an increase in disease severity, but rather the variant’s ability to evade existing immunity. Here is a comprehensive look at the BA.3.2 variant, its spread, and what it means for public health.

What is the Cicada Variant?

The BA.3.2 variant, or “Cicada,” is a highly divergent strain of SARS-CoV-2. It earned its nickname given that it remained largely “underground” for an extended period after its initial discovery, much like the insect for which it is named.

What sets BA.3.2 apart from previous strains is its genetic composition. The variant contains approximately 70 to 75 mutations. According to research cited by the CDC, these spike protein mutations allow the strain to efficiently evade antibodies, which emphasizes the ongoing need for genomic surveillance to evaluate the effectiveness of current vaccines and antivirals.

Timeline of Detection and Global Spread

The Cicada variant was first identified on November 22, 2024, in a respiratory sample collected in South Africa. Following its initial discovery, it began appearing in Africa, Asia, Europe, North America, and Oceania.

Key milestones in its spread include:

• September 2025: A notable uptick in detections began worldwide.
• June 2025: The variant was first detected in the U.S. At the San Francisco airport from a traveler arriving from the Netherlands.
• January 2026: The first official U.S. Case was reported.
• February 11, 2026: BA.3.2 had been reported in 23 different countries.

Impact and Presence in the United States

The CDC is utilizing a multimodal genomic surveillance approach—including traveler-based and wastewater monitoring—to track the variant’s footprint. In the U.S., BA.3.2 has been identified in:

• Clinical samples from five patients.
• Nasal swabs from four travelers.
• Three airplane wastewater samples.
• 132 wastewater samples across 25 different states.

As of March 14, 2026, tracking data indicates that BA.3.2 made up about 3.7% of collected wastewater samples. Despite its growth, it is not currently the dominant strain. The XFG variant remains the most prevalent at 53%, followed by LF.7 at 10.3%.

Severity and Vaccine Effectiveness

Currently, there is no evidence that the Cicada variant makes people sicker than previous versions of the virus. The main focus for medical professionals is “immune escape”—the potential for the virus to bypass antibodies gained from previous infections or vaccinations.

To combat evolving strains, the 2025–26 COVID-19 vaccines utilize 8.1 antigens. Monitoring the spread of BA.3.2 provides critical data that helps health organizations determine if the virus is successfully evading these protections.

The Broader Public Health Context

The emergence of BA.3.2 occurs against a backdrop of significant respiratory illness. According to the CDC, the 2024-25 respiratory season resulted in between 390,000 and 550,000 hospitalizations and 45,000 to 64,000 deaths.

Because the virus continues to mutate to survive and thrive, health officials stress the importance of ongoing observational evaluations of antiviral and vaccine effectiveness. Continuous surveillance ensures that medical responses can be adjusted as new lineages emerge.

Frequently Asked Questions

Is the Cicada variant more dangerous?

Based on current reports, BA.3.2 does not appear to make people more sick than previous variants. The primary concern is its ability to evade antibodies rather than an increase in clinical severity.

Do current vaccines work against BA.3.2?

The CDC is currently monitoring the variant to determine its ability to evade immunity from previous vaccinations. The 2025–26 vaccines use 8.1 antigens as part of the effort to keep pace with evolving strains.

How is the CDC tracking this variant?

The CDC uses a multimodal approach, which includes analyzing clinical samples, nasal swabs from travelers, and wastewater samples from across the United States.